139 related articles for article (PubMed ID: 8286928)
1. Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice.
Temsamani J; Tang JY; Padmapriya A; Kubert M; Agrawal S
Antisense Res Dev; 1993; 3(3):277-84. PubMed ID: 8286928
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal S; Temsamani J; Tang JY
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7595-9. PubMed ID: 1881900
[TBL] [Abstract][Full Text] [Related]
3. Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs.
Temsamani J; Kubert M; Tang J; Padmapriya A; Agrawal S
Antisense Res Dev; 1994; 4(1):35-42. PubMed ID: 8061514
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
Zhang R; Iyer RP; Yu D; Tan W; Zhang X; Lu Z; Zhao H; Agrawal S
J Pharmacol Exp Ther; 1996 Aug; 278(2):971-9. PubMed ID: 8768755
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
Sands H; Gorey-Feret LJ; Cocuzza AJ; Hobbs FW; Chidester D; Trainor GL
Mol Pharmacol; 1994 May; 45(5):932-43. PubMed ID: 8190109
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
8. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
[TBL] [Abstract][Full Text] [Related]
9. Capped oligodeoxynucleotide phosphorothioates. Pharmacokinetics and stability in mice.
Temsamani J; Tang JY; Agrawal S
Ann N Y Acad Sci; 1992 Oct; 660():318-20. PubMed ID: 1340145
[No Abstract] [Full Text] [Related]
10. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
[TBL] [Abstract][Full Text] [Related]
11. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.
Agrawal S; Zhang X; Lu Z; Zhao H; Tamburin JM; Yan J; Cai H; Diasio RB; Habus I; Jiang Z
Biochem Pharmacol; 1995 Aug; 50(4):571-6. PubMed ID: 7646565
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
Zhang R; Diasio RB; Lu Z; Liu T; Jiang Z; Galbraith WM; Agrawal S
Biochem Pharmacol; 1995 Mar; 49(7):929-39. PubMed ID: 7741765
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
[TBL] [Abstract][Full Text] [Related]
14. The clearance and degradation of oligodeoxynucleotides following intravenous injection into rabbits.
Goodchild J; Kim B; Zamecnik PC
Antisense Res Dev; 1991; 1(2):153-60. PubMed ID: 1841657
[TBL] [Abstract][Full Text] [Related]
15. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
18. Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.
Kairemo KJ; Tenhunen M; Jekunen AP
Anticancer Drug Des; 1996 Sep; 11(6):439-49. PubMed ID: 8836109
[TBL] [Abstract][Full Text] [Related]
19. Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data.
Kairemo KJ; Tenhunen M; Jekunen AP
Antisense Nucleic Acid Drug Dev; 1996; 6(3):215-20. PubMed ID: 8915506
[TBL] [Abstract][Full Text] [Related]
20. Renal uptake of an 18-mer phosphorothioate oligonucleotide.
Oberbauer R; Schreiner GF; Meyer TW
Kidney Int; 1995 Oct; 48(4):1226-32. PubMed ID: 8569084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]